ASH 2023 | Targeting CD38 with a bispecific antibody to treat R/R AML: a Phase I trial
Guru Subramanian Guru Murthy, MD, Medical College of Wisconsin, Milwaukee, WI, discusses a Phase I dose-escalation trial (NCT05038644) investigating XmAb18968, a CD38-targeting bispecific antibody, in the treatment of relapsed/refractory (R/R) acute myeloid leukemia (AML). With dose escalation from 0.8mg to above 1.3mg, this agent was well-tolerated, with predominantly low-grade cytokine release syndrome (CRS) and no dose-limiting toxicities (DLTs), and showed evidence of preliminary efficacy. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Amgen; Honoraria: Cardinal Health, BeiGene, Kite, Pfizer; Advisory board: Cardinal Health, BeiGene, Kite, Pfizer; Speakers Bureau: Rigel
